Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 215-220

  Deraco, Marcello ^a   Kusamura, Shigeki ^a   Virzì, Salvatore ^b   Puccio, Francesco ^c   MacRì, Antonio ^d   Famulari, Ciro ^d   Solazzo, Massimiliano ^c   Bonomi, Serena ^b   Iusco, Domenico Rosario ^b   Baratti, Dario ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Azienda USL di Bologna   (Italy)

^c Azienda Ospedaliera di Desenzano   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cytoreductive surgery; Epithelial ovarian cancer; Hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis; peritonectomy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; BLADDER FISTULA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL ANASTOMOSIS; CYTOREDUCTIVE SURGERY; ENDOSCOPIC THERAPY; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; INTERVENTIONAL RADIOLOGY; ITALY; MINIMAL RESIDUAL DISEASE; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REOPERATION; SEPSIS; SURGICAL DRAINAGE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 79960470553     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.004     Document Type: Article

References (49)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
3. W.P. McGuire, W.J. Hoskin, M.F. Brady, P.R. Kucera, E.E. Patridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
4. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
5. S. Tangjitgamol, S. Manusirivithaya, M. Laopaiboon, P. Lumbiganon, and A. Bryant Interval debulking surgery for advanced epithelial ovarian cancer Cochrane Database Syst Rev 2010 Oct 6;10:CD006014.
6. I. Vergote, C.G. Tropé, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
7. T.J. Herzog, R.L. Coleman, and M. Markman The role of maintenance therapy and novel taxanes in ovarian cancer Gynecol Oncol 102 2006 218 225 (Pubitemid 44041636)
8. V.J. Verwaal, S. van Ruth, E. de Bree, G.W. van Sloothen, H. van Tinteren, and H. Boot Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer J Clin Oncol 21 2003 3737 3743 (Pubitemid 46606227)
9. P.H. Sugarbaker New standard of care for appendiceal epithelial neoplasm with pseudomyxoma peritonei syndrome Lancet Oncol 1 2006 69 76 (Pubitemid 43025395)
10. D. Elias, F. Gilly, and F. Boutitie Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study J Clin Oncol 28 2010 63 68
11. T.D. Yan, M. Deraco, and D. Baratti Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience J Clin Oncol 27 2009 6237 6242
12. M. Deraco, P. Casali, M.G. Inglese, D. Baratti, E. Pennacchioli, and R. Bertulli Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion J Surg Oncol 83 3 2003 147 153 (Pubitemid 36807942)
13. C.W. Helm The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer Oncologist 14 2009 683 694
14. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259 (Pubitemid 34177431)
15. D.S. Chi, E.L. Eisenhauer, O. Zivanovic, Y. Sonoda, N.R. Abu-Rustum, and D.A. Levine Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm Gynecol Oncol 114 2009 26 31
16. D.S. Alberts, P.Y. Liu, and E.V. Hannigan Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1996 1950 1955 (Pubitemid 26428219)
17. M. Markman, B.N. Bundy, and D.S. Alberts Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynaecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007 (Pubitemid 32176274)
18. D.K. Armstrong, B. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
19. M. Look, D. Chang, and P.H. Sugarbaker Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum Int J Gynecol Cancer 14 2004 35 41 (Pubitemid 38280621)
20. P. Piso, M.H. Dahlke, M. Loss, and H.J. Schlitt Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer World J Surg Oncol 2 2004 21
21. K.S. Ryu, J.H. Kim, H.S. Ko, J.W. Kim, W.S. Ahn, and Y.G. Park Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer Gynecol Oncol 94 2004 325 332 (Pubitemid 39024534)
22. F. Raspagliesi, S. Kusamura, J.C. Campos Torres, G.A. de Souza, A. Ditto, and F. Zanaboni Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan Eur J Surg Oncol 32 2006 671 675 (Pubitemid 44063998)
23. A. Di Giorgio, E. Naticchioni, D. Biacchi, S. Sibio, F. Accarpio, and M. Rocco Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer Cancer 113 2008 315 325
24. T.C. Chua, G. Robertson, W. Liauw, R. Farrell, T.D. Yan, and D.L. Morris Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results J Cancer Res Clin Oncol 135 2009 1637 1645
25. M. Markman Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer. A critical need for an evidence-based evaluation Gynecol Oncol 113 2008 4 5
26. G.D. Aletti, H.J. Long, K.C. Podratz, and W.A. Cliby Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 104 2007 212 216 (Pubitemid 46070191)
27. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655 (Pubitemid 13149996)
28. P.H. Sugarbaker Peritonectomy procedures Ann Surg 221 1995 29 42
29. M. Deraco, D. Baratti, S. Kusamura, B. Laterza, and M.R. Balestra Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies J Surg Oncol 100 2009 321 328
30. C.R. Rossi, M. Foletto, and S. Mocellin Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study Cancer 94 2002 492 499 (Pubitemid 34081381)
31. P. Jaquet, and P.H. Sugarbaker Current methodologies for clinical assessment of patients with peritoneal carcinomatosis J Exp Clin Cancer Res 15 1996 49 58 (Pubitemid 26130826)
32. http://ctep.cancer.gov/forms/CTCAEv3.pdf
33. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 9332 2002 505 515
34. M.A. Steller, M.J. Egorin, E.L. Trimble, D.L. Bartlett, E.G. Zuhowski, and H.R. Alexander A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer Cancer Chemother Pharmacol 43 2 1999 106 114 (Pubitemid 29045027)
35. S.M. Eisenkop, N.M. Spirtos, and W.M. Lin "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary Gynecol Oncol 103 2006 329 335 (Pubitemid 44389875)
36. S.M. Eisenkop, N.M. Spirtos, R.L. Friedman, W.C. Lin, A.L. Pisani, and S. Perticucci Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study Gynecol Oncol 90 2003 390 396 (Pubitemid 36952033)
37. K. Jaaback, and N. Johnson Intraperitoneal chemotherapy for the initial management of primary epithelial EOC Cochrane Database Syst Rev 1 2006 CD005340.
38. R.E. Bristow Advanced cytoreductive surgery in gynecologic oncology Gynecol Oncol 114 2 Suppl 2009 S1 S2
39. K. Rowan Intraperitoneal therapy for EOC: why has it not become standard? J Natl Cancer Inst 101 2009 775 777
40. J. Pfisterer, B. Weber, and A. Reuss Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced EOC: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 2006 1036 1045 (Pubitemid 44288151)
41. S.M. Eisenkop, and N.M. Spirtos What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial EOC? Gynecol Oncol 82 2001 489 497 (Pubitemid 32826449)
42. S.C. Crawford, P.A. Vasey, J. Paul, A. Hay, J.A. Davis, and S.B. Kaye Does aggressive surgery only benefit patients with less advanced EOC? Results from an international comparison within the SCOTROC-1 Trial J Clin Oncol 23 2005 8802 8811 Erratum in: J Clin Oncol 2006;24:1224. (Pubitemid 46211526)
43. S.F. Adams, D.A. Levine, and M.G. Cadungog Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous EOC Cancer 115 2009 2891 2902
44. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
45. T.C. Chua, T.D. Yan, A. Saxena, and D.L. Morris Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality Ann Surg 249 2009 900 907
46. C.G. Gerestein, R.A. Damhuis, C.W. Burger, and G.S. Kooi Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review Gynecol Oncol 114 2009 523 527
47. A. Gadducci, E. Sartori, F. Landoni, P. Zola, T. Maggino, and A. Maggioni Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study J Clin Oncol 23 4 2005 751 758 (Pubitemid 46224174)
48. J. Warwick, S. Kehoe, H. Earl, D. Luesley, C. Redman, and K.K. Chan Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials Br J Cancer 72 6 1995 1513 1517 (Pubitemid 26002666)
49. P.M. Flynn, J. Paul Scottish Gynaecological Cancer Trials Group Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol 86 3 2002 354 357 (Pubitemid 35425534)